![Quiver Logo](/static/img/logo-icon.png)
![DCTH logo](https://quiver-logos.s3.us-east-2.amazonaws.com/dcth.png)
Delcath Systems Inc
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DCTH Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of DCTH by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by DCTH's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to DCTH
Recent picks made for DCTH stock on CNBC
ETFs with the largest estimated holdings in DCTH
Flights by private jets registered to DCTH
![Quiver Logo](/static/img/logo-icon.png)